سعر تريبليكسام Triplixam‏ 10/2.5/5مجم 15 قرص 2026

Triplixam 10/2.5/5 mg film-coated tablets (perindopril arginine/indapamide/amlodipine), pack of 15, Servier (Egypt).

• Most commonly reported with the components: hypokalaemia, dizziness, headache, paraesthesia, somnolence, dysgeusia, visual impairment, tinnitus, vertigo, palpitations, flushing, hypotension, cough, dyspnoea, gastrointestinal disorders, pruritus, rash, muscle spasms, ankle swelling, asthenia, oedema and fatigue.International label, same product · South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository

• Hypersensitivity to the active substances, other sulfonamides, dihydropyridines, other ACE inhibitors or excipients; history of angioedema with previous ACE-inhibitor therapy; hereditary or idiopathic angioedema.International label, same product · South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository
• Severe renal impairment, bilateral renal artery stenosis or stenosis of a single functioning kidney, dialysis patients; moderate renal impairment for the 10/2.5 mg perindopril/indapamide strengths.International label, same product · South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository
• Hypertrophic obstructive cardiomyopathy, aortic stenosis / left ventricular outflow tract obstruction, untreated decompensated heart failure, haemodynamically unstable heart failure after acute myocardial infarction, severe hypotension, shock including cardiogenic shock.International label, same product · South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository

• Angioedema of the face, extremities, lips, tongue, glottis and/or larynx may occur at any time; discontinue promptly. Laryngeal involvement may be fatal.International label, same product · South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository
• Neutropenia/agranulocytosis, thrombocytopenia and anaemia reported with ACE inhibitors; extreme caution in collagen vascular disease, immunosuppressant therapy, allopurinol or procainamide, especially with renal impairment.International label, same product · South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository
• Dual blockade of the renin-angiotensin-aldosterone system (ARBs or aliskiren) increases the risk of hypotension, hyperkalaemia and decreased renal function and is not recommended.International label, same product · South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository

• Sacubitril/valsartanContraindicated (angioedema risk); allow 36 hours between the last dose of one and the start of the other.South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository
• Racecadotril, mTOR inhibitors (sirolimus, everolimus, temsirolimus), gliptinsIncreased risk of angioedema.South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository
• Medicines increasing serum potassium (potassium salts, potassium-sparing diuretics, ARBs, NSAIDs, heparins, ciclosporin, tacrolimus, trimethoprim)Risk of hyperkalaemia; potassium-sparing diuretics contraindicated, others with caution and potassium monitoring.South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository

• Contraindicated during pregnancy; patients planning pregnancy should be changed to alternative antihypertensive treatment.International label, same product · South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository
• Contraindicated during lactation; amlodipine is excreted in human milk.International label, same product · South African Health Products Regulatory Authority (SAHPRA) PI/PIL repository

English text not available for this section.